Compare DexCom, Inc. (DXCM) vs Eos Energy Enterprises Inc (EOSE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Eos Energy Enterprises Inc — how do they compare? DexCom, Inc. trades at $77.21 (market cap $28.06B), while Eos Energy Enterprises Inc trades at $3.98 (market cap $1.55B). The key difference: DexCom, Inc. is far larger — about 18.1× Eos Energy Enterprises Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | EOSE | |
|---|---|---|
Market Cap | $28.06B | $1.55B |
Sector | Health | Energy |
52-Week High | $89.53 | $19.19 |
52-Week Low | $54.84 | $4.29 |
Enterprise Value | $27.03B | $1.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Eos Energy Enterprises (EOSE) trades at $3.99, down 6.99% on the day, reflecting a challenging fundamental picture with significant losses. The company reported a net loss of $969.65M on $114.20M revenue for 2025, though recent Q1 2026 results showed a surprise EPS beat. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while the stock is consolidating near a key $4 support level. Recent news highlights accelerating commercial execution, including a major project selection for the Golden Dome initiative and preliminary Q2 2026 results pointing to record quarterly revenue and backlog.
The outlook presents a high-risk, high-reward scenario. Significant revenue acceleration and project backlog growth offer potential upside, supported by a consensus analyst price target of $9.00 (125% upside). However, deep negative margins, substantial cash burn, and a highly leveraged balance sheet with 91.87% debt-to-asset ratio pose severe financial risks. Investment success hinges on the company's ability to achieve manufacturing scale and path to profitability in the competitive energy storage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →
